Tue. 6 Feb 2024, 8:05am ET
Benzinga
Government, News, Regulations
Boston Scientific Corporation (NYSE:BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the WaveWriter™ SCS Systems for the treatment of chronic low back and leg pain in people without prior back surgery, commonly referred to as non-surgical back pain (NSBP).